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http://www.biomedcentral.com/1471-2407/14/272RESEARCH ARTICLE Open AccessSecond primary cancer risk - the impact of
applying different definitions of multiple primaries:
results from a retrospective population-based
cancer registry study
Aishah Coyte1, David S Morrison2 and Philip McLoone2*Abstract
Background: There is evidence that cancer survivors are at increased risk of second primary cancers. Changes in
the prevalence of risk factors and diagnostic techniques may have affected more recent risks.
Methods: We examined the incidence of second primary cancer among adults in the West of Scotland, UK,
diagnosed with cancer between 2000 and 2004 (n = 57,393). We used National Cancer Institute Surveillance
Epidemiology and End Results and International Agency for Research on Cancer definitions of multiple primary
cancers and estimated indirectly standardised incidence ratios (SIR) with 95% confidence intervals (CI).
Results: There was a high incidence of cancer during the first 60 days following diagnosis (SIR = 2.36, 95% CI = 2.12
to 2.63). When this period was excluded the risk was not raised, but it was high for some patient groups; in
particular women aged <50 years with breast cancer (SIR = 2.13, 95% CI = 1.58 to 2.78), patients with bladder
(SIR = 1.41, 95% CI = 1.19 to 1.67) and head & neck (SIR = 1.93, 95% CI = 1.67 to 2.21) cancer. Head & neck cancer
patients had increased risks of lung cancer (SIR = 3.75, 95% CI = 3.01 to 4.62), oesophageal (SIR = 4.62, 95% CI = 2.73
to 7.29) and other head & neck tumours (SIR = 6.10, 95% CI = 4.17 to 8.61). Patients with bladder cancer had raised
risks of lung (SIR = 2.18, 95% CI = 1.62 to 2.88) and prostate (SIR = 2.41, 95% CI = 1.72 to 3.30) cancer.
Conclusions: Relative risks of second primary cancers may be smaller than previously reported. Premenopausal
women with breast cancer and patients with malignant melanomas, bladder and head & neck cancers may benefit
from increased surveillance and advice to avoid known risk factors.
Keywords: Second primary cancer, Relative risk, Survival, Scotland, Cancer registryBackground
The prevalence of patients living after a diagnosis of
cancer has increased due to rising incidence and im-
proving survival [1-3]. Patients often seek information
on preventing and detecting further cancer occurrence
[4,5]. There is therefore an increasing need to determine
the risk of subsequent cancer and to provide appropriate
surveillance and behaviour modification advice.
The risk of further primary cancers might be expected
to be raised because of persisting effects of genetic and* Correspondence: philip.mcloone@glasgow.ac.uk
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unless otherwise stated.behavioural risk factors, long term side-effects of
chemo- and radiotherapy, and increased diagnostic sen-
sitivity. There is some evidence that this is the case [6].
For female breast cancer, the risk of contralateral breast
cancer is 3% after 5 years [7] a four-fold increase [8,9].
Risks of second primary colorectal cancers are doubled
[10] but might only be increased in tumours of the prox-
imal colon [11]. A five-fold increase in risk of primary
lung cancers following Hodgkin’s lymphoma has been
reported [12] and risks of second primary head & neck
cancers are raised [13].
A new evaluation of second primary cancer risk is
needed for several reasons. There have been significant
temporal changes in the prevalence of risk factors – suchtd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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[16] - which may affect cancer incidence among survivors
of cancer. Diagnostic sensitivity has increased due to
screening programmes [17,18] and the increased use of
medical imaging technologies [19,20]. Registries use vari-
ous rules to distinguish between cancers that are new
cases and those that are an extension of an existing cancer.
The criteria for defining second primary cancers have
changed over time and differ between studies. Two sets of
rules are widely used; the rules of the Surveillance Epi-
demiology and End Results (SEER) Program [21] are used
mainly by North American cancer registries; the rules de-
veloped by the International Association of Cancer Regis-
tries (IACR) and the International Agency for Research on
Cancer (IARC) [22,23] are used internationally, mainly for
reporting. SEER takes account of histology, site, laterality
and time since initial diagnosis to identify multiple pri-
mary cancers. The IARC/IACR rules are more exclusive;
only one tumour is registered for an organ, irrespective of
time, unless there are histological differences.
Our aim was to describe second primary cancers in a
large geographically defined population over a period
when increasing detection, greater diagnostic sensitivity
and improved survival may have altered previous esti-
mates of risk. We used Scottish cancer registry data,
which have a high case ascertainment rate for most
tumour types [24-26], and applied comprehensive and
restricted definitions of second primary cancers.
Methods
Population
Using the Scottish Cancer Registry we identified all pa-
tients resident in the West of Scotland (population 2.4
million), aged ≥15 years who had a first diagnosis of a
malignant primary cancer between January 2000 and
December 2004 (n = 58,364). Diagnoses were coded to
the International Classification of Diseases 10th revision
(ICD-10). We ignored registrations of non-melanoma
skin cancers (ICD-10 C44). A cancer was deemed to be
a first incident, or index, cancer if there was no prior
record of cancer since 1980 and the cancer was recorded
as a malignant primary cancer (International Classifica-
tion of Diseases for Oncology behaviour code 3). We ex-
cluded patients whose index cancer was diagnosed at
date of death (n = 965). Six patients were excluded be-
cause date of death was recorded as preceding date of
incidence. The final sample comprised 57,393 patients.
We excluded the first sixty days of follow up from the
main analysis because it is difficult to distinguish be-
tween synchronous and metachronous tumours during
this period.
When cancer occurred at the same index cancer site
we recorded the subsequent cancer as a primary cancer
according to International Agency for Research onCancer/International Association of Cancer Registries
(IACR/IARC) rules [22,23] and also Surveillance Epi-
demiology and End Results (SEER) rules for reporting
multiple primaries. We applied IARC/IACR rules using
IARCcrgTools [27]. IARC/IACR only allow one tumour
(depending on histologic group) per organ or pair of or-
gans per person per lifetime. SEER rules were applied
using the multiple primary and histology coding manual
[28]. SEER rules take account of histology, site, laterality
and time since diagnosis.
Statistical methods
The relative risk of a second primary cancer was esti-
mated by indirect standardisation. The person-years at
risk among patients diagnosed with a first primary can-
cer were calculated from diagnosis until 5 years later,
date of death or date of diagnosis of a second primary
cancer, whichever came first. Data were stratified by site
of first primary cancer, site of second primary cancer,
sex and age at first diagnosis. The expected number of
second cancers in each stratum was estimated by multi-
plying the total number of person-years by the age, sex
and cancer specific incidence rate in the population of
the West of Scotland in each year between 2000 and
2009. Standardised incidence ratios (SIR) were obtained
by dividing the observed number of cases of second pri-
mary cancer by the number expected. This provided an
estimate of the risk of a cancer patient developing a sec-
ond primary cancer relative to the incidence of cancer in
the West of Scotland general population. Relative risks
are presented with exact 95% confidence intervals for
Poisson counts. Rates of second cancer incidence were
expressed per 100 person-years and age and sex standar-
dised to the European standard population. STATA ver-
sion 11 (StataCorp, CollegeStation, TX, USA) was used
to conduct statistical analyses.
Ethics
Formal ethical approval was unnecessary because the
analysis employed routinely collected non-patient identi-
fiable data. The use of these data for research purposes
has been approved by the Privacy Advisory Committee
to the Board of NHS National Services Scotland.
Results
We identified 57,393 patients with an incident primary
cancer. Five percent (2966/57393) were diagnosed with a
further primary cancer within 5 years of diagnosis. Six-
teen percent of second cancers (487/2966) were diag-
nosed on the same day as the index cancer. A further
12% (342/2966) were diagnosed between one to sixty
days after first diagnosis. The crude rate was 4.0 per 100
person-years in the first sixty days (Table 1). Over the
5 years of follow-up the rate was 2.0 per 100 person-
Table 1 Number of second primary cancers and person-years of follow up
Time since primary cancer
diagnosis
Second cancers*
(n)
Person-years
(years)
Crude rate (per 100
person-years)
Standarised rate†
(per 100 person-years)
0 days 487 0 - -
1- 60 days 342 8605 4.0 2.1
61 days - 1 year 455 33365 1.4 0.7
>1 -5 years 1682 103464 1.6 0.8
0-5 years 2966 145435 2.0 1.0
*excluding non-melanoma skin cancer.
†age & sex standardised (European standard population ages 15 to 85+).
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incidence ratios (SIR) for men and women. The risk in
the first 60 days was 3 times the population risk for
women and 2 times the risk for men. Between 60 days
and 1 year risks were lower than the reference popula-
tion. The overall SIR between 1 day-5 years was 1.07
(95%CI = 1.03 to 1.11) for both sexes combined.
The age, sex and 5-year survival of the 56,564 patients
who did not have a cancer in the first 60 days is sum-
marised in Table 2. Forty seven percent were aged 70
and over, sixty one percent died within five years, and
2137 (3.8%) had a second primary cancer.
Table 2 shows there was concordance in the order of
first and second primary cancers. Lung cancer com-
prised 19% and 24% of first and second cancers, respect-
ively; colorectal cancer comprised 13% and 15%; and
female breast cancer represented 15% and 11%. Five year
survival and the proportion of patients who had a fur-
ther cancer were associated. One to two percent of pa-
tients with cancers with poor survival (6-25% alive atFigure 1 Standardised incidence ratios (SIR) for subsequent primary c5 years for lung, oesophagus, ovarian, and stomach can-
cer) had a further primary cancer. The proportion of
second cancers among patients with cancers with better
survival (37-79% alive at 5 years) ranged from 4% for
colorectal to 8.5% for head & neck cancers.
Compared to the distribution of index cancers sites
(Table 2), there were higher proportions of head & neck
cancers (13% vs. 4% of index cancers) among patients
with lung cancer, higher proportions of lung cancer
(43% vs. 19%) among head & neck cancer patients, and
higher proportions of prostate (28% vs. 9%) and lung
cancers (36% vs. 19%) among patients with bladder can-
cer. P < 0.0001 for each comparison.
Later cancers at the same site may be recurrences ra-
ther than true primaries. Table 3 shows the number of
registered subsequent primary cancers, in the same ICD-
10 category as the index cancer, classified by IARC/IACR
and SEER rules. In each case SEER included a greater
number of second primaries than IARC/IACR. Female
breast cancer showed the greatest difference; 79 of 98ancers.
Table 2 Baseline characteristics and outcomes
Site of first primary cancer
All cancer*
(C00-C97)
Lung
(C33-34)
Colorectal
(C18-20)
Female
breast
(C50)
Prostate
(C61)
Head & neck
(C00-14, C30-32)
Stomach
(C16)
Bladder
(C67)
Oesophagus
(C15)
Melanoma
(C43)
Ovarian
(C56)
n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Total 56564 10764 (19.0) 7225 (12.8) 8386 (14.8) 5269 (9.3) 2398 (4.2) 2079 (3.7) 1832 (3.2) 1780 (3.1) 1696 (3.0) 1325 (2.3)
Men 27561 (48.7) 5894 (54.8) 3834 (53.1) 5269 (100.0) 1697 (70.8) 1262 (60.7) 1233 (67.3) 1094 (61.5) 736 (43.4)
Mean age (SD) years 66.6 (13.8) 70.0 (10.2) 69.9 (11.7) 62.0 (14.3) 71.6 (9.1) 63.3 (12.2) 70.6 (11.7) 71.8 (10.5) 69.8 (11.6) 55.5 (18.0) 63.8 (14.7)
Age (years)
15– < 50 6386 (11.3) 345 (3.2) 388 (5.4) 1660 (19.8) 42 (0.8) 277 (11.6) 113 (5.4) 46 (2.5) 85 (4.8) 646 (38.1) 219 (16.5)
50– < 70 23787 (42.1) 4513 (41.9) 2868 (39.7) 4089 (48.8) 2098 (39.8) 1385 (57.8) 763 (36.7) 658 (35.9) 735 (41.3) 619 (36.5) 599 (45.2)
70+ 26391 (46.7) 5906 (54.9) 3969 (54.9) 2637 (31.4) 3129 (59.4) 736 (30.7) 1203 (57.9) 1128 (61.6) 960 (53.9) 431 (25.4) 507 (38.3)
Number of patients with second
primary cancer*
2137 (3.8) 119 (1.1) 324 (4.5) 363 (4.3) 342 (6.5) 204 (8.5) 46 (2.2) 140 (7.6) 26 (1.5) 102 (6.0) 20 (1.5)
Second or later cancer
Lung (C33-34) 507 (23.7) 24 (20.2) 65 (20.1) 67 (18.5) 91 (26.6) 88 (43.1) 13 (28.3) 50 (35.7) 6 (23.1) 14 (13.7) 3 (15.0)
Colorectal (C18-20) 315 (14.7) 11 (9.2) 56 (17.3) 52 (14.3) 80 (23.4) 17 (8.3) 8 (17.4) 15 (10.7) 6 (23.1) 9 (8.8) 1 (5.0)
Female Breast (C50) 237 (11.1) 14 (11.8) 25 (7.7) 98 (27.0) (0.0) 5 (2.5) 6 (13.0) 3 (2.1) 0 (0.0) 15 (14.7) 6 (30.0)
Prostate (C61) 162 (7.6) 11 (9.2) 45 (13.9) (0.0) 3 (0.9) 11 (5.4) 3 (6.5) 39 (27.9) 1 (3.8) 8 (7.8) 0 (0.0)
Head & neck (C00-C14, C30-C32) 107 (5.0) 15 (12.6) 12 (3.7) 11 (3.0) 15 (4.4) 32 (15.7) 2 (4.3) 2 (1.4) 5 (19.2) 2 (2.0) 0 (0.0)
Stomach (C16) 83 (3.9) 6 (5.0) 16 (4.9) 7 (1.9) 22 (6.4) 6 (2.9) 3 (6.5) 7 (5.0) 0 (0.0) 0 (0.0) 0 (0.0)
Bladder (C67) 78 (3.6) 8 (6.7) 9 (2.8) 6 (1.7) 20 (5.8) 9 (4.4) 2 (4.3) 1 (0.7) 2 (7.7) 3 (2.9) 0 (0.0)
Oesophagus (C15) 73 (3.4) 4 (3.4) 7 (2.2) 9 (2.5) 10 (2.9) 18 (8.8) 1 (2.2) 3 (2.1) 1 (3.8) 3 (2.9) 0 (0.0)
Melanoma (C43) 84 (3.9) 2 (1.7) 8 (2.5) 17 (4.7) 14 (4.1) 0 (0.0) 1 (2.2) 2 (1.4) 0 (0.0) 28 (27.5) 2 (10.0)
Pancreas (C25) 49 (2.3) 1 (0.8) 12 (3.7) 10 (2.8) 7 (2.0) 1 (0.5) 1 (2.2) 5 (3.6) 0 (0.0) 4 (3.9) 0 (0.0)
Ovarian (C56) 34 (1.6) 0 (0.0) 3 (0.9) 19 (5.2) (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 0 (0.0) 1 (1.0) 1 (5.0)
Kidney (C64) 52 (2.4) 6 (5.0) 7 (2.2) 7 (1.9) 11 (3.2) 4 (2.0) 1 (2.2) 0 (0.0) 1 (3.8) 2 (2.0) 0 (0.0)
Corpus uteri (C54) 42 (2.0) 1 (0.8) 9 (2.8) 20 (5.5) (0.0) 2 (1.0) 1 (2.2) 0 (0.0) 1 (3.8) 0 (0.0) 3 (15.0)
All other cancers* 314 (13.9) 16 (12.9) 50 (14.7) 40 (10.6) 69 (19.2) 11 (4.8) 4 (8.5) 13 (8.8) 3 (11.1) 13 (11.9) 4 (19.0)
Number of deaths 34648 (61.3) 10130 (94.1) 4283 (59.3) 2429 (29.0) 2169 (41.2) 1262 (52.6) 1835 (88.3) 1157 (63.2) 1629 (91.5) 373 (22.0) 879 (66.3)
*excluding non-melanoma skin cancer.
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Table 3 Number of same site second primary cancers
Number of subsequent same site
primary cancers‡
Registry IARC/IACR
rules
SEER
rules
First primary cancer n n n
Lung (C33-34) 24 8 17
Colorectal (C18-20) 56 31 55
Female Breast (C50) 98 1 79
Prostate (C61) 3 0 0
Head & neck (C00-C14, C30-C32) 32 24 29
Stomach (C16) 3 0 1
Bladder (C67) 1 0 1
Oesophagus (C15) 1 0 0
Melanoma (C43) 28 0 28
Pancreas (C25) 1 0 0
Ovarian (C56) 1 0 1
Kidney (C64) 3 0 2
Corpus uteri (C54) 1 0 1
Abbreviations: SEER Surveillance Epidemiology and End Results, IARC
International Agency for Research on Cancer, IACR International Association of
Cancer Registries.
‡diagnosed >60 days- 5 years after first primary cancer.
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maries by SEER but only 1 by IARC. For malignant mel-
anoma, all 28 subsequent melanomas were identified as
second primaries by SEER but none by IARC/IACR
rules. There was a smaller difference for head & neck
cancers, for which SEER and IARC/IACR included 29
and 24 of 32 subsequent head & neck cancers.
Table 4 shows the relative risk of second primary cancers
using all registrations, all registrations applying IARC/
IACR and SEER rules, and all registrations excluding same
site cancers. There was no overall difference in cancer inci-
dence compared to the general population (SIR = 0.96,
95% CI = 0.91 to 1.00; SIR = 0.99, 95% CI = 0.94 to 1.04
excluding same site cancers). IARC/IACR rules, which
excluded the largest number of subsequent cancers, sug-
gested a lower risk (SIR = 0.86, 95% CI = 0.81 to 0.90).
Patients with lung, colorectal, breast (aged ≥50 years),
prostate and ovarian cancers were at lower risk of further
cancers compared with the general population. IARC/
IACR and SEER rules reduced the estimated risks further.
Patients with cancers of the head & neck, bladder, and
breast (women aged <50 years) showed statistically signifi-
cant raised rates of subsequent cancers. Patients with ma-
lignant melanoma had raised risks of second cancers using
all registrations and SEER rules; however, IARC/IACR
rules suggested no excess risk.
Figures 2 and 3 shows SIRs for 13 common second or
further primaries within 5 years of first diagnosis of lung,
colorectal, breast, prostate, bladder and head & neckcancer. SIRs based on IARC/IACR and SEER rules are also
shown. For primary lung cancer, lower risks of colorectal
cancer (SIR = 0.53, 95% CI = 0.26 to 0.94) and higher risks
of head & neck cancers (SIR = 2.60, 95% CI = 1.45 to 4.28)
were observed (Figure 2). When IARC/IACR and SEER
rules were applied, the risk of subsequent lung cancer was
significantly lower. For primary colorectal cancers there
were no significant differences in risk for each cancer
compared to the reference population, although there was
a suggestion of an increased risk of endometrial cancer
(SIR = 1.95, 95% CI = 0.89 to 3.71). Applying IARC/IACR,
but not SEER, rules reduced the estimated risk of subse-
quent colorectal cancer. Prostate cancer patients experi-
enced lower rates of lung (SIR = 0.81, 95% CI = 0.65 to
1.00), oesophageal (SIR = 0.55, 95% CI = 0.26 to 1.01) and
prostate cancers (SIR = 0.03, 95% CI = 0.01 to 0.09), and a
non-significant higher rate of melanoma (SIR = 1.38, 95%
CI = 0.76 to 2.32). Women with primary breast cancers
also had a non-significant raised risk of malignant melan-
oma (SIR = 1.64, 95% CI = 0.96 to 2.63). Risks of second
primary breast cancers were no different from the refer-
ence population but estimates were significantly lower
(SIR = 0.01, 95% CI = 0 to 0.06) applying IARC rules.
Among head & neck patients (Figure 3) there were signifi-
cantly raised risks of lung cancers (SIR = 3.75, 95% CI =
3.01 to 4.62), oesophageal (SIR = 4.62, 95% CI = 2.73 to
7.29) and head & neck cancers (SIR = 6.10, 95% CI = 4.17
to 8.61). SEER or IARC/IACR rules did not significantly
change SIRs for second head & neck cancers. Patients with
primary bladder cancers had raised risks of cancers of
the lung (SIR = 2.18, 95% CI = 1.62 to 2.88) and prostate
(SIR = 2.41, 95% CI = 1.72 to 3.30).
Standardised incidence ratios for selected cancers are
shown in Table 5. Between 60 days and 1 year after diag-
nosis, rates of second primary cancers were generally
lower than the reference population. When either IARC/
IACR or SEER rules were applied, rates of second primary
cancers were lower than rates based on all registrations.
Among patients alive one year after diagnosis, risks of fur-
ther cancers were raised in women with breast cancer
aged ≥50 years (SIR = 2.32, 95% CI =1.71 to 3.07) and pa-
tients with head & neck cancers (SIR =2.10, 95% CI = 1.80
to 2.44). Risks of cancers among prostate cancer survivors
at 1 year were significantly lowered (SIR = 0.69, 95% CI =
0.61 to 0.78). One-to-five-year risks were similar to the
general population among patients with cancers of the
lung, colorectum and breast (aged ≥50 years) although
IARC exclusions meant that risks were significantly
lowered in patients with colorectal and breast cancers
(aged ≥50 years).
Discussion
We found an overall raised risk of second primary can-
cer among patients with a first malignancy (SIR = 1.07).
Table 4 Standardised incidence ratios of second primary cancers at >60 days - 5 years
Registry IARC/IACR rules SEER rules Registry‡
First primary cancer Number with
second cancer
SIR (95% CI) Number with
second cancer
SIR (95% CI) Number with
second cancer
SIR (95% CI) Number with
second cancer
SIR‡ (95% CI)
Lung (C33-34) 119 0.79 (0.65, 0.94) 105 0.69 (0.57, 0.84) 112 0.74 (0.61, 0.89) 98 0.83 (0.67, 1.01)
Colorectal (C18-20) 324 0.89 (0.80, 1.00) 301 0.83 (0.74, 0.93) 323 0.89 (0.80, 1.00) 271 0.86 (0.76, 0.97)
Female breast (C50) 363 0.96 (0.86, 1.06) 272 0.71 (0.63, 0.80) 348 0.92 (0.82, 1.02) 274 0.96 (0.85, 1.08)
Age <50 52 2.13 (1.58, 2.78) 25 1.02 (0.65, 1.50) 49 2.00 (1.48, 2.64) 28 1.67 (1.11, 2.42)
Age ≥50 311 0.88 (0.78, 0.98) 247 0.69 (0.61, 0.78) 299 0.84 (0.75, 0.94) 246 0.92 (0.81, 1.04)
Prostate (C61) 342 0.71 (0.63, 0.79) 339 0.70 (0.63, 0.78) 323 0.89 (0.80, 1.00) 339 0.88 (0.79, 0.98)
Head & neck (C00-C14, C30-C32) 204 1.93 (1.67, 2.21) 196 1.85 (1.60, 2.13) 201 1.90 (1.64, 2.18) 176 1.74 (1.49, 2.02)
Stomach (C16) 46 1.05 (0.77, 1.40) 43 0.98 (0.71, 1.32) 44 1.00 (0.73, 1.35) 43 1.02 (0.74, 1.38)
Bladder (C67) 140 1.41 (1.19, 1.67) 138 1.39 (1.10, 1.55) 140 1.41 (1.19, 1.67) 139 1.46 (1.23, 1.73)
Oesophagus (C15) 26 0.80 (0.52, 1.17) 25 0.77 (0.50, 1.13) 25 0.77 (0.50, 1.13) 25 0.80 (0.51, 1.18)
Melanoma (C43) 102 1.35 (1.10, 1.64) 75 0.98 (0.77, 1.23) 102 1.35 (1.10, 1.64) 75 1.01 (0.79, 1.27)
Ovarian (C56) 19 0.61 (0.36, 0.95) 18 0.58 (0.34, 0.91) 19 0.61 (0.37, 0.95) 18 0.60 (0.36, 0.95)
All of above 1685 0.96 (0.91, 1.00) 1512 0.86 (0.81, 0.90) 1637 1.00 (0.95, 1.05) 1458 0.99 (0.94, 1.04)
‡excluding same site.
Abbreviations: SEER Surveillance Epidemiology and End Results, IARC International Agency for Research on Cancer, IACR International Association of Cancer Registries, SIR standardised incidence ratio, CI confidence interval.
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Figure 2 Standardised incidence ratios (SIR) for specific second primary cancers among patients with lung, colorectal, prostate and
breast cancer.
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days were excluded. However, the risk was raised for pa-
tients with specific cancers. Women aged <50 years with
cancer of the breast and patients with melanoma, blad-
der and head & neck cancers were at increased risk.
Patients with lung cancer were at increased risk of sub-
sequent head & neck cancers and patients with head &
neck cancers were at increased risk of lung cancer, as
well as oesophageal and other head & neck tumours. Pa-
tients with bladder cancers were at increased risk of lung
and prostate cancer.Studies have reported relative risks of second primary
cancers ranging from 1.08 to 1.3 [6,29-31]. Patients with
cancer may be at increased risk of further primary can-
cers for three main reasons: they are subject to intensive
investigations and ongoing surveillance; genetic and be-
havioural risk factors for the initial cancer may persist;
and treatment, particularly radiotherapy and chemother-
apy, may increase the risk of future malignancies.
We found a raised risk of second cancer diagnosis dur-
ing the first 60 days, suggesting an artefact of investiga-
tion. Crocetti observed a similar overall raised risk to
Figure 3 Standardised incidence ratios (SIR) for specific second primary cancers among patients with head and neck cancer, and
bladder cancer.
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in the first two months were excluded [31]. However,
Youlden observed larger risks (SIRs of 1.2 and 1.4 in
men and women, respectively) which remained 10 years
later [30]. Curtis found that raised risks were greatest in
recent years (1995–2000) which may reflect increasingly
sensitive diagnostic investigation [6].Table 5 Standardised incidence ratios of second primary canc
Regi
First primary cancer Time since diagnosis SIR (
Lung cancer (C33-34) 61 days- < 1 year 0.55
1-5 years 0.98
Colorectal cancer (C18-20) 61 days- < 1 year 0.79
1-5 years 0.93
Prostate cancer (C61) 61 days- < 1 year 0.77
1-5 years 0.69
Breast cancer (C50) age < 50 61 days- < 1 year 1.05
1-5 years 2.32
Breast cancer (C50) age≥ 50 61 days- < 1 year 0.75
1-5 years 0.91
Head & neck (C00-C14, C30-C32) 61 days- < 1 year 1.33
1-5 years 2.10
‡excluding same site.
Abbreviations: SEER Surveillance Epidemiology and End Results, IARC International A
Registries, SIR standardised incidence ratio, CI confidence interval.The most prevalent lung cancer risk factor is cigarette
smoking. This could explain the increased risk of other
smoking-related cancers among patients with lung or
head & neck cancer [32]. A similar association may ex-
plain the increase in lung cancer found among patients
with bladder cancer. However, clinical investigation of
abnormalities in anatomically adjacent sites is likely toer by time since diagnosis
stry IARC/IACR SEER Registry‡
95% CI) SIR (95% CI) SIR (95% CI) SIR (95% CI)
(0.39, 0.76) 0.47 (0.32, 0.66) 0.38 (0.27, 0.53) 0.58 (0.39, 0.82)
(0.78, 1.22) 0.88 (0.69, 1.11) 0.95 (0.75, 1.18) 1.04 (0.81, 1.32)
(0.61, 1.00) 0.73 (0.56, 0.94) 0.78 (0.60, 0.99) 0.81 (0.61, 1.04)
(0.82, 1.05) 0.86 (0.75, 0.98) 0.93 (0.82, 1.05) 0.88 (0.77, 1.01)
(0.61, 0.96) 0.75 (0.59, 0.94) 0.75 (0.59, 0.94) 0.94 (0.74, 1.18)
(0.61, 0.78) 0.69 (0.61, 0.78) 0.69 (0.61, 0.78) 0.87 (0.77, 0.98)
(0.29, 2.70) 0.53 (0.06, 1.90) 0.79 (0.16, 2.31) 1.11 (0.23, 3.25)
(1.71, 3.07) 1.11 (0.70, 1.66) 2.22 (1.63, 2.96) 1.77 (1.15, 2.62)
(0.56, 0.98) 0.65 (0.47, 0.87) 0.68 (0.50, 0.90) 0.84 (0.61, 1.13)
(0.80, 1.02) 0.70 (0.61, 0.81) 0.88 (0.77, 1.00) 1.16 (1.02, 1.32)
(0.91, 1.88) 1.25 (0.84, 1.78) 1.29 (0.88, 1.83) 1.05 (0.67, 1.56)
(1.80, 2.44) 2.02 (1.73, 2.36) 2.07 (1.77, 2.41) 1.94 (1.64, 2.27)
gency for Research on Cancer, IACR International Association of Cancer
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http://www.biomedcentral.com/1471-2407/14/272increase detection and this could explain the excess of
prostate cancers found among patients with bladder can-
cer. Fabbri suggested this for increased prostate and kid-
ney cancers among men with bladder cancer [33,34].
Mellemkjaer reported an SIR of 1.25 for all cancers in
women with a primary breast cancer [35]. We found an
SIR of 2.13 among women aged <50 years with breast
cancer, but applying the same IARC/IACR rules as
Mellemkjaier, we observed no excess risk. Women with
breast cancer appeared to have a raised risk of melan-
oma. There have been reports of increased melanoma
among patients with prostate and breast cancer [36]. A
confounding factor is that prostate and breast cancers
have relatively high survival and incidence is highest
among socio-economic well-off groups, as is melanoma.
Patients with an index cutaneous melanoma are at in-
creased risk of second primary melanomas [37]. This is
most likely due to the multifocal effects of ultraviolet
light exposure on the skin.
Our finding that patients with lung, colorectal, female
breast (ages ≥50 years), prostate and ovarian cancer had
lower than expected numbers of later cancers is not con-
sistent with previous reports [38-40]. This may be be-
cause we excluded cancers in the first two months,
when rates have been found to be highest. Cancers de-
tected within two months of the index cancer may
otherwise have not been diagnosed until sometime later,
if at all.
Our study covered a large population with a high inci-
dence of cancer and used recent cancer registry data.
Most tumour registries collect data on only malignant
and in situ neoplasms. The Scottish Cancer Registry col-
lects information on all new cases of cancer including
primary malignant neoplasms, carcinoma in situ, neo-
plasms of uncertain behaviour and benign brain and
spinal cord tumours. The guidelines for registering mul-
tiple primary cancers are not as restrictive as the IARC/
IACR rules, although they have some features in com-
mon. As a general rule clinical/pathological opinions of
second primary cancers are registered. IARC/IACR rules
are generally used for reporting purposes. We applied
both SEER and IARC/IACR rules, and explored the ef-
fect of excluding certain subsequent cancers. We did
find there were cancers recorded in the registry that
would be excluded as primary tumours according to
IARC/IACR rules. We do not know how many add-
itional notifications might have been included using
SEER rules but were never entered onto the registry.
The IARC/IACR rules may undercount multiple tu-
mours, because cancers with the same site and histology,
diagnosed more than 2 months apart but excluded as a
later primary, may actually represent a new tumour.
However to include these cancers could over count mul-
tiple tumours. Conversely, a new primary cancer may bemisdiagnosed as a recurrence or metastasis. Our registry
data found that 5% of cancer patients had a registration
of a second primary cancer within 5 years. In contrast a
study in the Netherlands, where the longest follow up
time was 18 years, found that the percentage of patients
who had a second cancer was 6% [41]. This difference
might be due to differences in registration practice.
We found a similar absolute risk to others, suggesting
that the smaller relative risk may be due to changing inci-
dence in the general, comparator population. Screening
programmes and initiatives to improve public awareness
of cancer have contributed to greater detection; expected
rates have risen and the relative risk for patients with an
index cancer may have fallen. We did not have informa-
tion on genetic risk factors, such as BRCA1, that might
identify clusters of cancers in high risk individuals.
Patients with head & neck cancers and women <50 years
old with breast cancer are at increased risk of subsequent
malignancies. The pattern of second cancers was similar
to that of first cancers and thus the advice to minimise ex-
posures to the 14 lifestyle and environmental factors de-
scribed by Parkin [42] remains valid. Further research is
needed to determine the effects of behaviour change and
previous exposure on subsequent risk. The higher rate of
malignant melanoma among patients with breast and
prostate cancer requires further investigation. Breast and
prostate cancer are socio-economically patterned and
higher rates could be due to healthcare seeking behaviour
which increases detection or, in the case of melanoma, to
increased sun exposure in more affluent patients. Analysis
of recent second primary cancer rates in other countries is
needed to test these hypotheses.
Conclusion
The relative risk of second primary cancers may be smaller
than previously reported, possibly because the general
population is subject to greater surveillance and screening.
Premenopausal women with breast cancer and patients
with malignancies of the bladder, head & neck, and cuta-
neous melanoma are at increased risk of second primary
cancers. It may be appropriate to offer surveillance and
advice to avoid known risk factors to these patients. Fur-
ther research is needed to determine whether previous
perspectives of increased second primary cancer risks have
been partly due to differences in detection.
Abbreviations
IACR: International Association of Cancer Registries; IARC: International
Agency for Research on Cancer; SEER: Surveillance Epidemiology and End
Results; SIR: Standardised incidence ratio; CI: Confidence interval.
Competing interests
The authors declare that they have no competing interests.
Authors’ contributions
This paper was based on a BSc (MedSci) project by AC. The study was
initially designed by DM and AC. AC carried out the original analysis. PM
Coyte et al. BMC Cancer 2014, 14:272 Page 10 of 11
http://www.biomedcentral.com/1471-2407/14/272redesigned and reanalysed the study. All authors contributed to the
interpretation of the data and the drafting of the paper. All authors read and
approved the final manuscript.
Acknowledgements
We thank Dr David Brewster, Director of the Scottish Cancer Registry, for his
helpful advice and comments on the manuscript.
Funding
PM and DSM were funded by their employer, the University of Glasgow; AC
received no funding.
Author details
1Undergraduate Medical School, School of Medicine, University of Glasgow,
Glasgow, UK. 2West of Scotland Cancer Surveillance Unit, Public Health
Research Group, Institute of Health and Wellbeing, University of Glasgow,
Glasgow, UK.
Received: 9 September 2013 Accepted: 7 April 2014
Published: 18 April 2014
References
1. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA
Cancer J Clin 2005, 55:74–108.
2. Maddams J, Brewster D, Gavin A, Steward J, Elliott J, Utley M, Moller H:
Cancer prevalence in the United Kingdom: estimates for 2008.
Br J Cancer 2009, 101:541–547.
3. Forman D, Stockton D, Moller H, Quinn M, Babb P, De Angelis R, Micheli A:
Cancer prevalence in the UK: results from the EUROPREVAL study.
Ann Oncol 2003, 14:648–654. http://dx.doi.org/10.1093/annonc/mdg169.
4. Rutten LJ, Arora NK, Bakos AD, Aziz N, Rowland J: Information needs and
sources of information among cancer patients: a systematic review of
research (1980–2003). Patient Educ Couns 2005, 57:250–261.
5. Mehnert A, Koch U, Sundermann C, Dinkel A: Predictors of fear of recurrence
in patients one year after cancer rehabilitation: a prospective study. Acta
Oncol 2013, 52:1102–1109. http://dx.doi.org/10.3109/0284186X.2013.765063.
6. Curtis RE, Freedman DM, Ron E, Ries LAG, Hacker DG, Edwards BK, Tucker
MA, Fraumeni JF Jr: New malignancies among cancer survivors: SEER Cancer
Registries, 1973–2000. NIH Publ. No. 05–5302. Bethesda, MD: National Cancer
Institute; 2006.
7. Gao X, Fisher SG, Emami B: Risk of second primary cancer in the
contralateral breast in women treated for early-stage breast cancer: a
population-based study. Int J Radiat Oncol Biol Phys 2003, 56:1038–1045.
http://dx.doi.org/10.1016/S0360-3016(03)00203-7.
8. Soerjomataram I, Louwman WJ, van der Sangen MJ, Roumen RM,
Coebergh JW: Increased risk of second malignancies after in situ breast
carcinoma in a population-based registry. Br J Cancer 2006, 95:393–397.
http://dx.doi.org/10.1038/sj.bjc.6603231.
9. Chen Y, Thompson W, Semenciw R, Mao Y: Epidemiology of contralateral
breast cancer. Cancer Epidemiol Biomarkers Prev 1999, 8:855–861.
10. Levi F, Randimbison L, Blanc-Moya R, Maspoli-Conconi M, Rosato V, Bosetti
C, La Vecchia C: High constant incidence of second primary colorectal
cancer. Int J Cancer 2013, 132:1679–1682.
11. Liu L, Lemmens VE, De Hingh IH, de Vries E, Roukema JA, van Leerdam ME,
Coebergh JW, Soerjomataram I: Second primary cancers in subsites of
colon and rectum in patients with previous colorectal cancer. Dis Colon
Rectum 2013, 56:158–168.
12. Ibrahim EM, Kazkaz GA, Abouelkhair KM, Al-Mansour MM, Al-Fayea TM,
Al-Foheidi M, Bayer AM, Elmasri OA: Increased risk of second lung cancer in
hodgkin’s lymphoma survivors: a meta-analysis. Lung 2013, 191:117–134.
13. Jegu J, Binder-Foucard F, Borel C, Velten M: Trends over three decades of
the risk of second primary cancer among patients with head and neck
cancer. Oral Oncol 2013, 49:9–14.
14. Scholes S, Bajekal M, Love H, Hawkins N, Raine R, O’Flaherty M, Capewell S:
Persistent socioeconomic inequalities in cardiovascular risk factors in England
over 1994–2008: a time-trend analysis of repeated cross-sectional data.
BMC Public Health 2012, 12:129. http://dx.doi.org/10.1186/1471-2458-12-129.
15. Hotchkiss JW, Davies C, Gray L, Bromley C, Capewell S, Leyland AH: Trends in
adult cardiovascular disease risk factors and their socio-economic
patterning in the Scottish population 1995–2008: cross-sectional surveys.
BMJ Open 2011, 1(1):e000176. http://dx.doi.org/10.1136/bmjopen-2011-000176.16. Howel D: Waist circumference and abdominal obesity among older
adults: patterns, prevalence and trends. PLoS One 2012, 7:e48528.
http://dx.doi.org/10.1371/journal.pone.0048528.
17. The NHS cancer screening programmes website.
[http://www.cancerscreening.nhs.uk/] Accessed: 19th March 2014.
18. Moser K, Sellars S, Wheaton M, Cooke J, Duncan A, Maxwell A, Michell M,
Wilson M, Beral V, Peto R, Richards M, Patnick J: Extending the age range
for breast screening in England: pilot study to assess the feasibility and
acceptability of randomization. J Med Screen 2011, 18:96–102.
http://dx.doi.org/10.1258/jms.2011.011065.
19. Groheux D, Espie M, Giacchetti S, Hindie E: Performance of FDG PET/CT in
the clinical management of breast cancer. Radiology 2013, 266:388–405.
20. Chopra A, Ford A, De Noronha R, Matthews S: Incidental findings on
positron emission tomography/CT scans performed in the investigation
of lung cancer. Br J Radiol 2012, 85:e229–e237. http://dx.doi.org/10.1259/
bjr/60606623.
21. Adamo MB, Johnson CH, Ruhl JL, Dickie LA: 2012 SEER Program Coding and
Staging Manual. NIH Publication number 12–5581. Bethesda, MD: National
Cancer Institute; 2012.
22. IARC/ENCR/IACR Working Group: International rules for multiple primary
cancers. Asian Pacific J Cancer Prev 2005, 6:104–106.
23. International Agency for Research on Cancer: International Rules for Multiple
Primary Cancers (ICD-O Third Edition). Internal Report No. 2004/02. Lyon: IARC; 2004.
24. Brewster D, Crichton J, Muir C: How accurate are Scottish cancer
registration data? Br J Cancer 1994, 70:954–959.
25. Brewster D, Muir C, Crichton J: Registration of lung cancer in Scotland: an
assessment of data accuracy based on review of medical records.
Cancer Causes Control 1995, 6:303–310.
26. Brewster D, Muir C, Crichton J: Registration of colorectal cancer in
Scotland: an assessment of data accuracy based on review of medical
records. Public Health 1995, 109:285–292.
27. Ferlay J, Burkhard C, Whelan S, Parkin DM: Check and conversion programs
for cancer registries (IARC/IACR Tools for Cancer Registries). IARC Technical
Report No. 42. Lyon: IARC; 2005. Available from http://www.iacr.com.fr/
TechRep42-MPrules.pdf. Accessed online 19th March 2014.
28. Johnson CH, Peace S, Adamo P, Fritz A, Percy-Laurry A, Edwards BK: The
2007 Multiple Primary and Histology Coding Rules. Bethesda, MD: National
Cancer Institute; 2007.
29. Dong C, Hemminki K: Second primary neoplasms in 633,964 cancer
patients in Sweden, 1958–1996. Int J Cancer 2001, 93:155–161.
30. Youlden DR, Baade PD: The relative risk of second primary cancers in
Queensland, Australia: a retrospective cohort study. BMC Cancer 2011,
11:83. http://dx.doi.org/10.1186/1471-2407-11-83.
31. Crocetti E, Buiatti E, Falini P: Multiple primary cancer incidence in Italy.
Eur J Cancer 2001, 37:2449–2456.
32. Atienza JA, Dasanu CA: Incidence of second primary malignancies in
patients with treated head and neck cancer: a comprehensive review of
literature. Curr Med Res Opin 2012, 28:1899–1909.
33. Kellen E, Kiyohara H: Multiple primary cancer (MPC) associated with
bladder cancer: an analysis of the clinical and autopsy cases in Japan.
Jpn J Clin Oncol 1985, 15(S1):201–210.
34. Fabbri C, Ravaioli A, Ravaioli A, Bucchi L, Balducci C, Canuti D, Desiderio F,
Foca F, Panzini I, Falcini F: Risk of cancer of the prostate and of the
kidney parenchyma following bladder cancer. Tumori 2007, 93:124–128.
35. Mellemkjaer L, Friis S, Olsen JH, Scelo G, Hemminki K, Tracey E, Andersen A,
Brewster DH, Pukkala E, McBride ML, Kliewer EV, Tonita JM, Kee-Seng C,
Pompe-Kirn V, Martos C, Jonasson JG, Boffetta P, Brennan P: Risk of second
cancer among women with breast cancer. Int J Cancer 2006, 118:2285–2292.
36. Yang GB, Barnholtz-Sloan JS, Chen Y, Bordeaux JS: Risk and survival of
cutaneous melanoma diagnosed subsequent to a previous cancer.
Arch Dermatol 2011, 147:1395–1402. http://dx.doi.org/10.1001/
archdermatol.2011.1133.
37. Schmid-Wendtner MH, Baumert J, Wendtner CM, Plewig G, Volkenandt M:
Risk of second primary malignancies in patients with cutaneous
melanoma. Br J Dermatol 2001, 145:981–985.
38. Thellenberg C, Malmer B, Tavelin B, Gronberg H: Second primary cancers
in men with prostate cancer: an increased risk of male breast cancer.
J Urol 2003, 169:1345–1348.
39. Hemminki K, Li X, Dong C: Second primary cancers after sporadic and
familial colorectal cancer. Cancer Epidemiol Biomarkers Prev 2001,
10:793–798.
Coyte et al. BMC Cancer 2014, 14:272 Page 11 of 11
http://www.biomedcentral.com/1471-2407/14/27240. Hemminki K, Aaltonen L, Li X: Subsequent primary malignancies after
endometrial carcinoma and ovarian carcinoma. Cancer 2003,
97:2432–2439.
41. Liu L, de Vries E, Louwman M, Aben K, Janssen-Heijnen M, Brink M,
Coebergh JW, Soerjomataram I: Prevalence of multiple malignancies in
the Netherlands in 2007. Int J Cancer 2011, 128:1659–1667.
http://dx.doi.org/10.1002/ijc.25480.
42. Parkin DM: The fraction of cancer attributable to lifestyle and
environmental factors in the UK in 2010. Br J Cancer 2011, 105:S2–S5.
http://dx.doi.org/10.1038/bjc.2011.474.
doi:10.1186/1471-2407-14-272
Cite this article as: Coyte et al.: Second primary cancer risk - the impact
of applying different definitions of multiple primaries: results from a
retrospective population-based cancer registry study. BMC Cancer
2014 14:272.Submit your next manuscript to BioMed Central
and take full advantage of: 
• Convenient online submission
• Thorough peer review
• No space constraints or color ﬁgure charges
• Immediate publication on acceptance
• Inclusion in PubMed, CAS, Scopus and Google Scholar
• Research which is freely available for redistribution
Submit your manuscript at 
www.biomedcentral.com/submit
